- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05764876
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws) (Trep-AByaws)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current principle of yaws eradication is based on a single round of mass drug administration of azithromycin (AZI) called total community treatment (TCT) followed by targeted treatment of active cases and close contacts every 6 months called total targeted treatment (TTT). Studies done in Papua New Guinea have shown that 3 rounds of TCT are preferable to 1 TCT followed by TTT rounds because it results in higher overall coverage, particularly of latent cases. In the context of repeated rounds of TTT and multiple rounds of TCT, resistance to AZI has ben detected on 5 patients with yaws Recent studies have been successful on the culture of Treponema pallidum (syphilis and yaws), therefore investigators are now able to identify more potential treatment for yaws and syphilis.
Yaws is one of the major causes of the Cutaneous Ulcer Disease (CUD) syndrome. The CUD syndrome is a painful and debilitating condition, endemic to remote tropical regions with poor sanitation and limited health care access affecting children mainly. In Papua New Guinea it is caused by a range of unknown and some known pathogens besides yaws that are not easily distinguished on clinical diagnosis. New information on the causative agents of the CUD syndrome is needed to facilitate its management with an integrated approach.
The aim of the project is to provide evidence supporting (or rejecting) the hypothesis that the use of linezolid (LZD) can be an alternative treatment to cure yaws corroborated by clinical, serological, and molecular methods. LZD is a very safe drug that has been delivered to adults and children for the treatment of cutaneous infections all over the world. Investigators will compare two different treatments: (A) linezolid (LZD) and (B) azithromycin (AZI). In addition, the investigators plan to contribute to characterize the etiology of the CUD syndrome. The study will be implemented in selected wards of the Islands Region of Papua New Guinea.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Oriol Mitjà, MD, PhD
- Phone Number: 0034609248887
- Email: omitja@lluita.org
Study Contact Backup
- Name: Camila G Beiras, PhD
- Phone Number: 0034609248887
- Email: cgonzalez@lluita.org
Study Locations
-
-
-
Port Moresby, Papua New Guinea
- Recruiting
- National Department of Health
-
Contact:
- Wendy Houinei, HEO
- Phone Number: +675 7124 7511
- Email: whouinei@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants 5-18 years identified during an active case search program at the elementary, primary and secondary schools in the Islands Region.
- CUD syndrome suspected due to yaws: one or more ulcerative or nodular or papilloma skin lesion of more than 1 cm in diameter.
- Positive treponemal (T1) and non-treponemal (T2) serology by Chembio dual path platform (DPP) syphilis screen & confirm assay (DPP test).
- Accepted and signed informed consent.
- Ability to comply with the requirements of the study protocol including follow up visits.
Exclusion Criteria:
- Children younger than 5 years old.
- Clinical late-stage possible yaws: destructive osteitis (rhinopharyngitis gangosa, sabre shins) or gummous nodules.
- Known allergy to LZD or AZI antibiotics.
- Pregnant or breastfeeding women.
- Refusal at ward level or village chief (for village inclusion), or refusal of individual or guardian (for individual inclusion).
- Have taken any antibiotics with potential activity against TPE within the last 7 days prior to randomization (i.e., beta lactams, cephalosporines, macrolides, tetracyclines).
- Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, bipolar disorder, incapacitating psycho-affective disturbance, acute confusional state.
- Renal function impairment requiring hemodialysis.
- Current treatment with any drugs likely to interact with the study medication
- Symptomatic concomitant infection requiring antibiotic treatment potentially active against TPE.
- Having received treatment for yaws in the last 6 months.
- Patients who are unable to take oral medication or having a gastrointestinal disease likely to interfere with drug absorption (including malnutrition and stomach flu).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Azithromycin
Participants in the control arm will receive standard treatment for yaws which azithromycin .
|
Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
Other Names:
|
Experimental: Linezolid
Participants in the experimental arm will receive oral linezolid treatment.
|
Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical resolution
Time Frame: 4 weeks after treatment
|
Proportion of patients with clinical resolution of yaws lesions (clinical cure).
Assessment of clinical resolution defined as the complete healing of lesions at 4 weeks from treatment start.
|
4 weeks after treatment
|
Serological cure
Time Frame: 24 weeks after treatment
|
Proportion of patients with adequate serological response (serological cure).
Assessment of sero-cure is described as a four-fold decline in rapid plasma reagin (RPR) titer or seroreversion at 24 weeks from treatment start.
|
24 weeks after treatment
|
Serological cure
Time Frame: 48 weeks after treatment
|
Proportion of patients with adequate serological response (serological cure).
Assessment of sero-cure is described as a four-fold decline in rapid plasma reagin (RPR) titer or seroreversion at 48 weeks from treatment start.
|
48 weeks after treatment
|
Relapse
Time Frame: 24 weeks after treatment
|
Proportion of patients with relapse (recurrent episodes caused by the same strain) (molecular cure).
Assessment of recurrence by molecular methods of Treponema pallidum ssp.
pertenue (TPE) DNA in ulcer swab to determine relapse or reinfection within 24 weeks from treatment start.
|
24 weeks after treatment
|
Relapse
Time Frame: 48 weeks after treatment
|
Proportion of patients with relapse (recurrent episodes caused by the same strain) (molecular cure).
Assessment of recurrence by molecular methods of Treponema pallidum ssp.
pertenue (TPE) DNA in ulcer swab to determine relapse or reinfection within 48 weeks from treatment start.
|
48 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lession (ulcer swab) TPE assessment
Time Frame: Baseline (before treatment)
|
Assessment of TPE strains by genomic molecular methods in ulcer swabs from patients with active yaws.
|
Baseline (before treatment)
|
Oral (oral swab) TPE assessment
Time Frame: Baseline (before treatment)
|
Assessment of TPE strains by genomic molecular methods in oral swabs from patients with active/latent yaws.
|
Baseline (before treatment)
|
Plasma TPE assessment
Time Frame: Baseline (before treatment)
|
Assessment of TPE strains by genomic molecular methods in plasma from patients with active/latent yaws.
|
Baseline (before treatment)
|
Allelic variation in recurrent cases
Time Frame: Baseline (before treatment)
|
Proportion of patients with allelic variation in TPE DNA in patients with recurrence or treatment failure.
|
Baseline (before treatment)
|
Identification of antibiotic resistance genotype.
Time Frame: 4 weeks after treatment
|
Proportion of patients with antibiotic resistance genotype.
|
4 weeks after treatment
|
Identification of other causes of cutaneous ulcer
Time Frame: Baseline (before treatment)
|
Proportion of patients with selected known and unknown causes of cutaneous ulcers (CU).
Assessment of etiological agents using polymerase chain reaction (PCR) for TPE, Haemophylus ducreyi (HD) and Streptoccocus pyogenes (SP).
|
Baseline (before treatment)
|
Safety of intervention (adverse events)
Time Frame: 48 weeks after treatment.
|
Proportion of patients with adverse events
|
48 weeks after treatment.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Camila Beiras, Fundació Lluita contra les Infeccions
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Trep-AByaws
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Yaws
-
Oriol MitjaThe University of Papua New Guinea; The Royal Botanic Gardens, KewCompletedYaws | Yaws; Cutaneous | Cutaneous UlcerPapua New Guinea
-
London School of Hygiene and Tropical MedicineFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la... and other collaboratorsActive, not recruitingYawsCôte D'Ivoire, Cameroon, Ghana
-
Lihir Medical CentreCentre For International HealthCompletedYaws | Treponema Infection | Neglected Tropical DiseasePapua New Guinea
-
London School of Hygiene and Tropical MedicineCenters for Disease Control and Prevention; World Health Organization; Barcelona... and other collaboratorsCompletedYawsUnited Kingdom, Ghana, Papua New Guinea
-
Oriol MitjaPapua New Guinea Institute of Medical Research; Barcelona Centre for International... and other collaboratorsCompleted
-
Lihir Medical CentreWorld Health Organization; Harvard School of Public Health (HSPH); Barcelona... and other collaboratorsCompleted
-
Lihir Medical CentreUniversity of Washington; World Health Organization; Barcelona Institute for... and other collaboratorsCompletedYawsPapua New Guinea
-
Lihir Medical CentreCompletedTrauma | Lymphatic Filariasis | YawsPapua New Guinea
-
London School of Hygiene and Tropical MedicineMurdoch Childrens Research Institute; Kirby Institute; Atoifi Adventist Hospital...CompletedYaws | Scabies | ImpetigoSolomon Islands
-
London School of Hygiene and Tropical MedicineAIM Initiative; Ministry of Health, LiberiaUnknownYaws | Leprosy | Lymphatic Filariases | Buruli UlcerLiberia
Clinical Trials on Azithromycin Oral Tablet
-
Population Health Research InstituteRecruitingHIV Disease ProgressionNigeria, Uganda, South Africa, Botswana, Ghana, Sierra Leone, Congo, Côte D'Ivoire, Ethiopia, Malawi, Mozambique, Rwanda, Tanzania, Zambia
-
Centre Hospitalier Intercommunal CreteilRecruitingSinusitis, Chronic | Sinus Infection ChronicFrance
-
Murdoch Childrens Research InstituteMinistry of Health, FijiCompletedBacterial InfectionsFiji
-
Bispebjerg HospitalLund University; University of Copenhagen; Herlev and Gentofte HospitalRecruitingImmune System Diseases | Lung Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma | COPD | Exacerbation Copd | Asthma; EosinophilicDenmark
-
Université de MontréalCentre de Recherche du Centre Hospitalier de l'Université de MontréalRecruiting
-
London School of Hygiene and Tropical MedicineCompletedNeonatal SEPSISBurkina Faso, Gambia
-
Prof. Dr. Umar FarooqAyub Medical College, AbbottabadUnknown
-
Cadrock Pty. Ltd.Centre for Digestive Diseases, AustraliaTerminatedCoronary Heart Disease | Chlamydophila Pneumoniae InfectionsAustralia
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada